- Peripheral T‑cell lymphoma, NOS in bone marrow and heart
-
Lee H, Lee J
- KMID: 2552887
- Blood Res.
- 2024;59:5.
- doi: 10.1007/s44313-024-00009-7
-
- CITED
-
- Close
- SHARE
-
- Close
- Genomic technologies for detecting structural variations in hematologic malignancies
-
Jang M
- KMID: 2552886
- Blood Res.
- 2024;59:1.
- doi: 10.1007/s44313-024-00001-1
Genomic structural variations in myeloid, lymphoid, and plasma cell neoplasms can provide key diagnostic, prog‑ nostic, and therapeutic information while elucidating the underlying disease biology. Several molecular diagnostic approaches play a central role in evaluating hematological malignancies.... -
- CITED
-
- Close
- SHARE
-
- Close
- Upregulation of lnc‑FOXD2‑AS1, CDC45, and CDK1 in patients with primary non‑M3 AML is associated with a worse prognosis
-
Manoochehrabadi S, Talebi M, Pashaiefar H, Ghafouri‑Fard S, Vaezi M, Omrani M, Ahmadvand M
- KMID: 2552883
- Blood Res.
- 2024;59:4.
- doi: 10.1007/s44313-024-00002-0
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with an unfavorable outcome. The present research aimed to identify novel biological targets for AML diagnosis and treatment. In this study, we per‑ formed an in-silico method to identify antisense... -
- CITED
-
- Close
- SHARE
-
- Close
- Real‑world incidence and risk factors of bortezomib‑related cardiovascular adverse events in patients with multiple myeloma
-
Jang B, Jeong J, Heo K, Koh Y, Lee J
- KMID: 2552884
- Blood Res.
- 2024;59:3.
- doi: 10.1007/s44313-024-00004-y
Background Although most studies on the cardiovascular toxicity of proteasome inhibitors have focused on carfil‑ zomib, the risk of cardiotoxicity associated with bortezomib remains controversial. This study aimed to evaluate the incidence and risk factors of cardiovascular adverse events (CVAEs) associated... -
- CITED
-
- Close
- SHARE
-
- Close
- Adding MYC/BCL2 double expression to NCCN‑IPI may not improve prognostic value to an acceptable level
-
Warnnissorn N, Kanitsap N, Niparuck P, Boonsakan P, Kulalert P, Limvorapitak W, Bhoopat L, Saengboon S, Suriyonplengsaeng C, Chantrathammachart P, Puavilai T, Chuncharunee S
- KMID: 2552885
- Blood Res.
- 2024;59:2.
- doi: 10.1007/s44313-024-00006-w
Background MYC/BCL2 double expression (DE) is associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). This study aimed to determine whether the addition of DE to the National Comprehensive Cancer Network... -
- CITED
-
- Close
- SHARE
-
- Close
